Claus A. Andersson - 09 Nov 2021 Form 4 Insider Report for IO Biotech, Inc. (IOBT)

Role
Director
Signature
/s/ Brian Burkavage, Attorney-in-Fact for Claus Andersson
Issuer symbol
IOBT
Transactions as of
09 Nov 2021
Net transactions value
+$1,050,000
Form type
4
Filing time
12 Nov 2021, 15:16:01 UTC
Previous filing
04 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IOBT Common Stock Conversion of derivative security +1,361,660 1,361,660 09 Nov 2021 See footnote F1, F3
transaction IOBT Common Stock Conversion of derivative security +354,830 +26% 1,716,490 09 Nov 2021 See footnote F2, F3
transaction IOBT Common Stock Purchase $1,050,000 +75,000 +4.4% $14.00* 1,791,490 09 Nov 2021 See footnote F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IOBT Series B Preferred Stock Conversion of derivative security $0 -147,881 -100% $0.000000* 0 09 Nov 2021 Common Stock 1,361,660 See footnote F1, F3
transaction IOBT Series C Preferred Stock Conversion of derivative security $0 -28,225 -100% $0.000000* 0 09 Nov 2021 Common Stock 354,830 See footnote F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series B Preferred Stock had no expiration date.
F2 Upon the closing of the IPO, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date.
F3 Sunstone Life Science Ventures Fund III K/S ("Sunstone Fund III"). Sunstone LSV General Partner III ApS ("Sunstone LSV GP III") is the general partner of Sunstone Fund III and has voting and dispositive power over all of the shares of held by Sunstone Fund III. The reporting person is a General Partner of Sunstone Life Science Ventures A/S and a member of the executive board of Sunstone LSV GP III, and shares voting and dispositive power with respect to the shares held by Sunstone Fund III. The reporting person disclaims beneficial ownership of the shares held directly by Sunstone Fund III except to the extent of his pecuniary interest therein.